Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business public offering

Yarrow Bioscience $150M Public Offering Pricing

Analysis based on 7 articles · First reported Sep 10, 2026 · Last updated Sep 14, 2026

Sentiment
5
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The offering provides Altor BioScience with roughly $150 million of fresh capital to advance its autoimmune thyroid disease pipeline, strengthening its balance sheet but diluting existing shareholders through the issuance of new shares. The deal is a routine follow-on equity raise for a clinical-stage biotech and is unlikely to move broader markets, though it may draw modest attention among healthcare-focused investors.

biotechnology pharmaceuticals investment banking

Altor BioScience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases, commenced and then priced an underwritten public offering of 5,769,231 shares of its common stock at $26.00 per share. The offering is expected to generate approximately $150 million in gross proceeds before deducting underwriting discounts, commissions, offering expenses and advisory fees. Yarrow also granted the underwriters a 30-day option to purchase up to an additional 865,384 shares at the public offering price, less underwriting discounts and commissions. The offering was expected to close on September 14, 2026, subject to customary closing conditions, and all securities were being offered by Yarrow. The company intends to use the net proceeds to fund research and development expenses for its pipeline, including its lead program YB-101, an anti-thyroid stimulating hormone receptor monoclonal antibody for Graves' disease and thyroid eye disease, as well as for general corporate purposes such as working capital and capital expenditures. Jefferies, Toronto-Dominion Bank — TD Cowen and Guggenheim Partners served as joint book-running managers, while LifeSci Capital acted as lead manager. The offering was conducted under a shelf registration statement on Form S-3 filed with the United States — United States Securities and Exchange Commission and declared effective on August 19, 2026.

90 Altor BioScience priced public offering
40 Altor BioScience commenced public offering
priv
Altor BioScience is the issuer of the offering, raising approximately $150 million in gross proceeds to fund its pipeline and general corporate purposes. The raise bolsters its cash position but dilutes existing shareholders.
Importance 100.0 Sentiment 10.0
priv
Jefferies served as a joint book-running manager for Altor BioScience's public offering, earning underwriting fees.
Importance 30.0 Sentiment 5.0
subs
Toronto-Dominion Bank — TD Cowen served as a joint book-running manager for Altor BioScience's public offering, earning underwriting fees.
Importance 30.0 Sentiment 5.0
priv
Guggenheim Partners served as a joint book-running manager for Altor BioScience's public offering, earning underwriting fees.
Importance 30.0 Sentiment 5.0
priv
LifeSci Capital acted as lead manager for Altor BioScience's public offering, earning underwriting fees.
Importance 20.0 Sentiment 5.0
govactor
The United States — United States Securities and Exchange Commission declared Altor BioScience's shelf registration statement on Form S-3 effective on August 19, 2026, enabling the offering.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.